Opportunity Information: Apply for RFA AI 09 016
Apply for RFA AI 09 016
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Partnerships for Development of Vaccines for Selected Pathogens (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Apr 3, 2009 and posted on Apr 3, 2009.
- Applicants must submit their applications by Jul 28, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $4,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities Independent school districts State governments Special district governments Small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses County governments Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH National Institute of Allergy and Infectious Diseases (NIAID) released this Funding Opportunity Announcement, RFA-AI-09-016, to support research projects that directly move vaccine candidates forward for a specific set of pathogens with major public health impact: cytomegalovirus (CMV), respiratory syncytial virus (RSV), Staphylococcus aureus, Pseudomonas aeruginosa, and Clostridium difficile. The central emphasis is on practical, development-oriented vaccine research rather than broad, open-ended basic science. In other words, the projects proposed are expected to generate concrete progress toward viable vaccines for one or more of these targets, such as advancing antigen discovery and selection, optimizing immunogen design, improving delivery platforms or adjuvants, strengthening preclinical proof-of-concept, and resolving translational hurdles that commonly block vaccine development for these organisms.
A defining feature of the announcement is its encouragement of partnerships. Applicants are strongly encouraged (though not strictly required) to form collaborative teams across disciplines and/or with industry. The intent is to bring together complementary expertise that a single lab or a single sector might not have alone, for example pairing academic immunology and microbiology strengths with clinical, manufacturing, regulatory, formulation, or product-development experience that can speed the path from concept to candidate. This collaborative framing signals that reviewers will likely value credible development plans, clear roles for collaborators, and access to specialized capabilities (such as relevant animal models, immunological assay platforms, bioprocessing know-how, or clinical trial readiness), even when the application is submitted by a single institution.
The award mechanism is the standard NIH R01 research project grant, meaning applicants propose a defined research plan with specific aims and a budget appropriate to the scope of work. NIAID projected a total commitment of about $4.0 million in total costs for FY2010 under this FOA, with an anticipated three to five awards. The size and duration of individual awards were expected to vary depending on what is proposed, and funding decisions were explicitly contingent on both appropriations and the availability of enough highly meritorious applications. The announcement lists an award ceiling of $500,000, which provides a sense of the maximum award size anticipated under the program parameters.
From an eligibility standpoint, the FOA is broad and inclusive. It allows applications from many types of U.S. organizations, including public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit entities (including small businesses and other for-profits), and a wide range of government bodies (state, county, city or township, special districts, independent school districts, and public housing authorities). It also explicitly includes tribal governments and tribal organizations, U.S. territories or possessions, and a number of mission-relevant institution types such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, faith-based or community-based organizations, and eligible federal agencies. Importantly, foreign (non-U.S.) organizations and regional organizations are also listed among eligible applicants, signaling that NIAID was open to strong proposals regardless of geography as long as they meet NIH requirements and address the FOA objectives.
Administratively, this opportunity is categorized as discretionary grant funding in the health area, associated with CFDA 93.856 (Microbiology and Infectious Diseases Research), and it does not require cost sharing or matching funds. The FOA was posted on April 3, 2009, with an application closing date of July 28, 2009, and it was later archived on August 28, 2009. The full announcement and requirements were made available through the NIH Grants Guide link provided in the notice, and NIH’s Office of Extramural Research (OER) webmaster contacts were listed for technical access or linking issues.
Overall, this R01 opportunity was designed to concentrate resources on a small number of projects capable of making measurable, development-relevant advances toward vaccines for five challenging and high-burden pathogens. It combines the flexibility of the R01 mechanism with a targeted set of pathogens and a clear preference for collaborative, partnership-driven approaches that can bridge the gap between academic discovery and real-world vaccine development milestones.
Frequently Asked Questions (FAQs)
What is the funding opportunity being offered?
This is an NIH National Institute of Allergy and Infectious Diseases (NIAID) Funding Opportunity Announcement (FOA) titled RFA-AI-09-016. It uses the NIH R01 research project grant mechanism to support vaccine-focused research and development projects.
What is the main goal of this FOA?
The goal is to fund research projects that directly move vaccine candidates forward for a defined set of pathogens with major public health impact. The emphasis is on practical, development-oriented vaccine research that produces concrete progress toward viable vaccine candidates.
Which pathogens are specifically targeted by this announcement?
The FOA targets vaccine development efforts for five organisms: cytomegalovirus (CMV), respiratory syncytial virus (RSV), Staphylococcus aureus, Pseudomonas aeruginosa, and Clostridium difficile.
Is this FOA focused on basic science or applied vaccine development?
The central emphasis is applied, development-oriented vaccine research rather than broad, open-ended basic science. Proposed projects are expected to show measurable, practical progress that advances vaccine candidates for the listed pathogens.
What kinds of activities or outcomes are considered responsive to the FOA?
Examples of responsive work mentioned include advancing antigen discovery and selection, optimizing immunogen design, improving delivery platforms or adjuvants, strengthening preclinical proof-of-concept, and addressing translational hurdles that commonly block vaccine development for these organisms.
Are collaborations or partnerships required?
Partnerships are strongly encouraged but not strictly required. The FOA signals that collaborative teams (including cross-disciplinary and/or industry partnerships) may be viewed favorably when they strengthen the development plan and provide needed capabilities.
What types of collaborators does NIAID seem to encourage for this FOA?
The FOA highlights collaborations that bring complementary expertise together, such as pairing academic strengths (immunology, microbiology) with clinical, manufacturing, regulatory, formulation, or product-development experience to speed the path toward a vaccine candidate.
What kinds of capabilities might strengthen an application under this FOA?
Based on the FOA description, reviewers may value credible development plans with clear collaborator roles and access to specialized resources such as relevant animal models, immunological assay platforms, bioprocessing know-how, or clinical trial readiness.
What grant mechanism is used for funding?
The FOA uses the standard NIH R01 research project grant mechanism, where applicants propose a defined research plan with specific aims and a budget appropriate to the scope of work.
How much total funding was NIAID planning to commit?
NIAID projected an overall commitment of about $4.0 million in total costs for FY2010 under this FOA.
How many awards were anticipated?
The FOA anticipated making approximately three to five awards.
Is there an award ceiling or maximum budget level mentioned?
Yes. The announcement lists an award ceiling of $500,000, indicating the maximum award size anticipated under the program parameters.
Will every award be the same size and duration?
No. The FOA states that the size and duration of individual awards were expected to vary depending on what is proposed.
Is funding guaranteed if an application is strong?
The FOA notes that funding decisions were contingent on appropriations and the availability of a sufficient number of highly meritorious applications.
Who is eligible to apply?
Eligibility is broad. The FOA allows applications from many types of U.S. organizations, including public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit entities (including small businesses), and a wide range of government bodies.
Are state and local government entities eligible?
Yes. The FOA includes multiple government entity types such as state, county, city or township governments, special districts, independent school districts, and public housing authorities.
Are tribal governments and tribal organizations eligible?
Yes. Tribal governments and tribal organizations are explicitly included among eligible applicants.
Are U.S. territories or possessions eligible?
Yes. The FOA explicitly includes U.S. territories or possessions among eligible applicants.
Are foreign (non-U.S.) organizations eligible?
Yes. Foreign (non-U.S.) organizations and regional organizations are listed among eligible applicants, indicating openness to strong proposals regardless of geography as long as NIH requirements are met and the proposal addresses the FOA objectives.
Are mission-relevant institution types specifically called out as eligible?
Yes. The FOA explicitly includes institution types such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and faith-based or community-based organizations, among others.
What is the CFDA number and program area associated with this opportunity?
The FOA is associated with CFDA 93.856, Microbiology and Infectious Diseases Research.
Does this opportunity require cost sharing or matching funds?
No. The FOA indicates that it does not require cost sharing or matching funds.
What type of funding is this categorized as?
It is categorized as discretionary grant funding in the health area.
When was the FOA posted and when was the application due?
The FOA was posted on April 3, 2009, and the application closing date was July 28, 2009.
Is this funding opportunity still active?
No. The FOA was later archived on August 28, 2009.
Where were the full announcement and requirements made available?
The FOA states that the full announcement and requirements were available through the NIH Grants Guide link provided in the notice.
Who was listed for technical help accessing the announcement link?
The FOA indicates that NIH Office of Extramural Research (OER) webmaster contacts were listed for technical access or linking issues.
What is the overall program design or strategy behind this FOA?
This R01 opportunity was designed to concentrate resources on a small number of projects capable of making measurable, development-relevant advances toward vaccines for the five targeted pathogens, with a clear preference for approaches that can bridge academic discovery and real-world vaccine development milestones.
Browse more opportunities from the same category: Health
Next opportunity: RECOVERY Air Force Fiscal Year 2009 American Recovery and Reinvestment Act Research Program
Previous opportunity: 1890 Facilities Grant Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 09 016
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 09 016) also looked into and applied for these:
| Funding Opportunity |
|---|
| Sober Truth on Preventing Underage Drinking Act Grants Apply for SP 09 007 Funding Number: SP 09 007 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: Case Dependent |
| NIDCD Definitive Phase III Clinical Trial Planning Grant (R34) Apply for PAR 09 142 Funding Number: PAR 09 142 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Implementation of Programs for the Prevention, Care and Treatment of HIV/AIDS in the United Republic of Tanzania under the President s Emergency Plan for AIDS Relief Apply for CDC RFA PS09 974 Funding Number: CDC RFA PS09 974 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $5,000,000 |
| Peer to Peer Capacity Building of Ministries of Health in Public Sector HIV Program Management under the President s Emergency Plan for AIDS Relief Apply for CDC RFA PS09 915 Funding Number: CDC RFA PS09 915 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $7,000,000 |
| Multiplex Assay Development for Arthritis and Musculoskeletal and Skin Diseases (SBIR R43/R44) Apply for PA 09 127 Funding Number: PA 09 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Preventing Complications of Bleeding Disorders through Health Education and Outreach Apply for CDC RFA DD09 905 Funding Number: CDC RFA DD09 905 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $750,000 |
| Hepatitis C Cooperative Research Centers (U19) Apply for RFA AI 09 025 Funding Number: RFA AI 09 025 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| EIS Ongoing Expansion Funds for Current Part C Grantees Apply for HRSA 09 219 Funding Number: HRSA 09 219 Agency: Health Resources and Services Administration Category: Health Funding Amount: $200,000 |
| Service Area Competitions Apply for HRSA 09 225 Funding Number: HRSA 09 225 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Research on Psychopathology In Intellectual Disabilities (Mental Retardation) (R01) Apply for PA 09 150 Funding Number: PA 09 150 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Basic Research on HIV Persistence (R01) Apply for PA 09 152 Funding Number: PA 09 152 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| International Centers of Excellence for Malaria Research (U19) Apply for RFA AI 09 017 Funding Number: RFA AI 09 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Promoting the Health of People with Clotting Disorders Apply for CDC RFA DD09 904 Funding Number: CDC RFA DD09 904 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $600,000 |
| Promoting Education and Outreach of Persons with Hereditary Blood Disorders Identifying Patients with Diamond Blackfan Anemia Apply for CDC RFA DD09 906 Funding Number: CDC RFA DD09 906 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $175,000 |
| Long Lasting Insecticide Treated Nets (LLINs) RFA Apply for M OAA GH 09 847 Funding Number: M OAA GH 09 847 Agency: Agency for International Development Category: Health Funding Amount: $100,000,000 |
| International Programs to Prevent and Control Micronutrient Malnutrition Apply for CDC RFA DP09 911 Funding Number: CDC RFA DP09 911 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $800,000 |
| Reducing Risks for an Alcohol Exposed Pregnancy (AEP) in High Risk Women Attending Sexually Transmitted Diseases (STD) Clinics in Urban Settings Apply for CDC RFA DD09 908 Funding Number: CDC RFA DD09 908 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $275,000 |
| Surveillance of Fetal Alcohol Syndrome (FAS) Utilizing the Infrastructure of Existing Surveillance Programs Apply for CDC RFA DD09 910 Funding Number: CDC RFA DD09 910 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $250,000 |
| Collaborative R01s for Clinical and Services Studies of Mental Disorders, AIDS and Alcohol Use Disorders (R01) Apply for PAR 09 153 Funding Number: PAR 09 153 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Early Diagnosis Cooperative Agreements Apply for CDC RFA PS09 9133 Funding Number: CDC RFA PS09 9133 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 09 016", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.